Transcode Therapeutics, Inc.
Public company- Headquarters
- BOSTON, Massachusetts
- Ticker
- RNAZ
- CIK
- 0001829635
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CFOThomas A. Fitzgerald, M.B.A. | Sep 11, 2026 | Departed |
| CFOJohn Tattory | Sep 11, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ENANTA PHARMACEUTICALS INC
CEO departs: Jay R. Luly, Ph.D.
- VERTEX PHARMACEUTICALS INC / MA
new member of the board of directors appointed: Daniel Brennan
- Ernexa Therapeutics Inc.
member of the Board appointed: Robert J. Spiegel, M.D.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- Executive departure
CFO departs: Thomas A. Fitzgerald, M.B.A.
Thomas A. Fitzgerald, M.B.A., Chief Financial Officer, principal financial officer and principal accounting officer of Transcode Therapeutics, Inc., resigns the role, effective September 9, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 11, 2026Role: Chief Financial Officer, principal financial officer and principal accounting officer
- Executive appointment
CFO appointed: John Tattory
John Tattory was named Interim Chief Financial Officer, principal financial officer and principal accounting officer of Transcode Therapeutics, Inc., effective September 9, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 11, 2026Role: Interim Chief Financial Officer, principal financial officer and principal accounting officer
Last verified Nov 8, 2026